A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder [Estudio multicentrico, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia del aripiprazol administrado en dosis fijas por via oral una vez al dia en nirios y adolescentes con síndrome de Gilles de la Tourette].

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder [Estudio multicentrico, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia del aripiprazol administrado en dosis fijas por via oral una vez al dia en nirios y adolescentes con síndrome de Gilles de la Tourette].

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2013 Planned End Date changed from 1 Oct 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 12 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top